KX-826: Long-Term Safety Results are out!
    10/16/2024

    From the encyclopedia
    Minoxidil β†’

    An essential vasodilator with some anti-androgenic effects

    Finasteride β†’

    Frontline, gold standard treatment for combatting androgenic alopecia

    At a glance
    In this research discussion post, the primary subjects mentioned are
    πŸ’§ KX-826 (topical) 0.5% 52 weeks
    β€’ Minoxidil
    the tone is 😐 neutral with initial improvement, decline after 24 weeks results.

    Other terms

    KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.
    View this post in the Community β†’

    Similar Community Posts Join

    6 / 6 results

      community Guys, we finally have an alternative to finasteride

      in Research/Science  263 upvotes 1 year ago
      A combination of pyrilutamide, minoxidil, and alfatradiol is proposed as an effective alternative to finasteride for treating mild to moderate hair loss, claiming to stabilize hair loss and improve thickness without finasteride's side effects. Some users are skeptical about the effectiveness and approval of these treatments, while others are interested in trying them due to finasteride's side effects.

      community Experience with only Minoxidil and Nizoral

      in Minoxidil  6 upvotes 11 months ago
      Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

      community Is this regrowth? My doctor took these photos and said I looked better.

      in Satire  142 upvotes 1 year ago
      The conversation humorously discusses an extensive and exaggerated hair loss treatment regimen, including finasteride, dutasteride, minoxidil, pyrilutamide, RU58841, and various other therapies. Despite the numerous treatments, the effectiveness is questioned, and the user humorously considers adding more minoxidil.

    Related Research

    6 / 6 results
      Androgenetic Alopecia: Therapy Update

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.
      The 100 Most Cited Articles in Androgenetic Alopecia: A Bibliometric Analysis

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.
      Recent Advances in Drug Development for Hair Loss

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
      A Decade of Progress in Androgenetic Alopecia Management: Emerging Therapies and Multimodal Strategies

      research A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies

      December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology”
      This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.